Evaluation of adipose‐derived stromal vascular fraction or bone marrow‐derived mesenchymal stem cells for treatment of osteoarthritis

Abstract

The purpose of this study was the assessment of clinical, biochemical, and histologic effects of intraarticular administered adipose-derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treatment of osteoarthritis. Osteoarthritis was induced arthroscopically in the middle carpal joint of all horses, the contralateral joint being sham-operated. All horses received treatment on Day 14. Eight horses received placebo treatment and eight horses received adipose-derived stromal vascular fraction in their osteoarthritis-affected joint. The final eight horses were treated the in osteoarthritis-affected joint with bone marrow-derived mesenchymal stem cells. Evaluations included clinical, radiographic, synovial fluid analysis, gross, histologic, histochemical, and biochemical evaluations. No adverse treatment-related events were observed. The model induced a significant change in all but two parameters, no significant treatment effects were demonstrated, with the exception of improvement in synovial fluid effusion PGE2 levels with bone marrow-derived mesenchymal stem cells when compared to placebo. A greater improvement was seen with bone marrow-derived mesenchymal stem cells when compared to adipose-derived stromal vascular fraction and placebo treatment. Overall, the findings of this study were not significant enough to recommend the use of stem cells for the treatment of osteoarthritis represented in this model.

Controlled Delivery of Transforming Growth Factor β1 by Self-Assembling Peptide Hydrogels Induces Chondrogenesis of Bone Marrow Stromal Cells and Modulates Smad2/3 Signaling

“…Finally, peptide-delivered TGFb1 was tested with encapsulated adult equine BMSCs to assess the potential for translating this technology to a large animal model widely used for translational studies of preclinical human therapies. 31 …”

Mesenchymal stem cell enhances chondral defects healing in horses

“…The nonsignificant differences in lameness scores are contrasted by observations of a reduction in PGE 2 concentrations in synovial fluid in the G1 joints [9,28]. This fact seems to suggest that PGE 2 is not closely related to the degree of lameness or clinical manifestations of pain, but only with generalized joint inflammation [29].…”

“…They present fibroblastic morphology and should adhere to plastic, show osteogenic, adipogenic and chondrogenic differentiation and express surface markers [6,7]. The benefits resulting from the use of MSC in chondral defects and osteoarthritis, such as tropism for injured cartilage, paracrine activity, cellular differentiation and proliferation, predict good results and more effective treatments [8][9][10].…”

Comparação de dois métodos de colheita de medula óssea de equinos e de dois meios de diluição para o isolamento de células mononucleares

“…No entanto, a quantidade ideal de células necessárias para implantação ainda é contraditório entre os autores tanto com relação à quantidade de células necessárias, como o tecido implantado e a espé- cie, uma vez que alguns afirmam que a quantidade celular de 2 x 10 6 é eficiente para terapia, como relatado por Tognoli et al (2009) em experimento feito em cães em tecido ocular, ou 2 x 10 7 (Hu et al 2007) em macacos em nervo periférico e ainda 3 x 10 6 células utilizadas também em nervo periférico de equinos (Moraes, 2012). Já outros estrapolam para valores como 10 x 10 6 células como evidenciado por Frisbie et al (2009) em experimento realizado com equinos no tratamento de osteoartite. Com base nas informações, conclui-se que a quantidade de CTA obtida nas colheitas A e B está dentro de uma margem aceitável e viável para o sucesso de um tratamento baseado na terapia celular, com exceção das colheitas no animal 1, que não atingiram o quantitativo celular preconizado pelo autor em questão.…”